FOSUN PHARMA (02196.HK): Taohong Siwu Decoction Granules Registration Application Accepted by NMPA

NewTimeSpace · 2026/05/13 19:36 · By Xuran Lin

NewTimeSpace News: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196.HK) announced that the drug registration application for Taohong Siwu Decoction Granules submitted by its controlling subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. has been accepted by the National Medical Products Administration (NMPA). As a Class 3.1 new traditional Chinese medicine, the formulation originates from Fuke Bingjian by Qing-dynasty physician Chai Dehua and is included in the First Catalogue of Ancient Classic Prescriptions issued by the State Administration of Traditional Chinese Medicine.

NewTimeSpace News: Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (02196.HK) released an overseas regulatory announcement on May 13, 2026. The drug registration application for Taohong Siwu Decoction Granules from its controlling subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd. has been officially accepted by the National Medical Products Administration.

The product is categorized as aClass 3.1 new traditional Chinese medicine. It nourishes blood, activates blood circulation and removes blood stasis, indicated for blood deficiency and blood stasis syndrome, including irregular menstruation, heavy menstruation with blood clots, dark purplish sticky menstrual discharge, abdominal pain and distension in female patients.

The prescription is derived fromFuke Bingjianby Chai Dehua in the Qing Dynasty and is listed in the First Catalogue of Ancient Classic Prescriptions of the State Administration of Traditional Chinese Medicine.

As of April 2026, the Group’s cumulative R&D investment in the product stood at approximately RMB 6.96 million (unaudited). Up to the announcement date, only two variants of Taohong Siwu Decoction Granules have been approved for marketing in mainland China.

Prior to commercial production, the product still needs to pass GMP compliance inspection and obtain official drug registration approval. The acceptance of this registration application is not expected to have a material impact on the Group’s current financial performance.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

FOSUN PHARMA 02196.HK drug registration application